STING-IN-4
Based on 1 Customer Validation
STING-IN-4 (Compound 1) is a STING inhibitor that inhibits STING expression and hence reducing activation of STING and nuclear factor-κB (NF-κB) signaling. STING-IN-4 shows anti-inflammatory activity and can be used for the research of sepsis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.87%
- CAS No.: 2250374-27-5
- Formule: C32H46N2O3
- Masse moléculaire:506.72
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
STING[1]
STING-IN-4 (Compound 1) (20 μM; 26 h) inhibits NO production induced by LPS in RAW264.7 cells[1].
STING-IN-4 (2.5-10 μM; 26 h) significantly inhibits the expression of iNOS in RAW264.7 cells[1].
STING-IN-4 (5 and 50 μM; 12 h) significantly reduces STING degradation at 49, 52, and 55 °C and it may have an ability to interact with STING and enhance thermal stabilization of STING[1].
STING-IN-4 (2.5-10 μM; 8 h) inhibits LPS-induced activation of STING/IRF3/NF-κB[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 cells
-
Concentration:2.5, 5 and 10 μM
-
Incubation Time:Pre-treated for 2 h followed LPS treatment for 6 h or 24 h
-
Result:Inhibited the expression of iNOS (24 h). Blocked LPS-induced phosphorylation of TBK1, IRF3, p65, and IκB-α (6 h).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice, LPS-induced acute liver injury model[1]
-
Dosage:1, 3 and 9 mg/kg
-
Administration:Intraperitoneal injection, daily for 3 days
-
Result:Significantly reduced the hemorrhage severity. Decreased the levels of alanine transaminase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) induced by LPS. Significantly reduced the levels of TNF-α, IL-6, and IFN-β compared with mice treated only with LPS. Markedly reduced the levels of STING, p-TBK, p-IRF3, p-p65, and p-IκB-α.
Chemical Information
-
CAS No. 2250374-27-5
-
Appearance Solid
-
Masse moléculaire 506.72
-
Formule C32H46N2O3
-
Color White to off-white
-
SMILES
C[C@@]12[C@]3([H])[C@]([C@]4(C([C@@]5([H])[C@@](CC4)(CCC(C)(C5)C)C(O)=O)=CC3)C)(CC[C@@]1([H])[C@@](C)(C6=NC=CN=C6C2)CO)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 93.33 mg/mL (184.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 3.5 mg/mL (6.91 mM); Clear solution
This protocol yields a clear solution of ≥ 3.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (35.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9735 mL | 9.8674 mL | 19.7348 mL | 49.3369 mL |
| 5 mM | 0.3947 mL | 1.9735 mL | 3.9470 mL | 9.8674 mL | |
| 10 mM | 0.1973 mL | 0.9867 mL | 1.9735 mL | 4.9337 mL | |
| 15 mM | 0.1316 mL | 0.6578 mL | 1.3157 mL | 3.2891 mL | |
| 20 mM | 0.0987 mL | 0.4934 mL | 0.9867 mL | 2.4668 mL | |
| 25 mM | 0.0789 mL | 0.3947 mL | 0.7894 mL | 1.9735 mL | |
| 30 mM | 0.0658 mL | 0.3289 mL | 0.6578 mL | 1.6446 mL | |
| 40 mM | 0.0493 mL | 0.2467 mL | 0.4934 mL | 1.2334 mL | |
| 50 mM | 0.0395 mL | 0.1973 mL | 0.3947 mL | 0.9867 mL | |
| 60 mM | 0.0329 mL | 0.1645 mL | 0.3289 mL | 0.8223 mL | |
| 80 mM | 0.0247 mL | 0.1233 mL | 0.2467 mL | 0.6167 mL | |
| 100 mM | 0.0197 mL | 0.0987 mL | 0.1973 mL | 0.4934 mL |
STING-IN-4 Related Classifications
HY-151970 Related Classifications
Powered by Bioz